Surgeons and clinical researchers: We are pleased to announce the call for study sites to join the Geistlich Pharma AG’s Chondro-Gide US Pivotal Trial.
The study has a unique design that will evaluate outcomes of Chondro-Gide use to treat large focal knee defects. Contact us via email at email@example.com.
With more than 80 peer reviewed publications, the Geistlich AMIC® Chondro-Gide® for the knee is the most widely published product in its category. AMIC®, or Autologous Matrix-Induced Chondrogenesis, performed in conjunction with Chondro-Gide®, a bioderived collagen membrane, is a 1-step treatment for repairing cartilage lesions.
Geistlich Surgery is now pleased to announce the SECURE study, a pivotal trial that will be conducted to secure regulatory clearance/approval in the United States. Geistlich Surgery is actively recruiting qualified clinical study sites to participate in this ground breaking initiative!